• Services for Regulatory ATMP Development
    Services for Regulatory ATMP Development

    Living biotherapeutics - Oncolytic viruses - AAV vectors

  • ATMP Biodistribution and Shedding Analysis
    ATMP Biodistribution and Shedding Analysis

    qPCR - CFU determination - Flow cytometry - EliSpot

  • MultiPlex miRNA Biomarker Discovery
    MultiPlex miRNA Biomarker Discovery

    Hydrogel particle-based >65-plex from small samples amounts

  • MultiPlex miRNA Clinical Profiling
    MultiPlex miRNA Clinical Profiling

    Pre-designed & custom >65-plex panels

Berlin Cures GmbH Publishes Promising Phase 1 Data Results

Berlin Cures GmbH is a clinical stage pharmaceutical company developing a short DNA aptamer BC 007 for the treatment of pathogenic autoantibodies against G-protein coupled receptors.

A dose-escalating study evaluated the safety, tolerability, pharmacokinetics and mode of action of BC 007 after a single intravenous infusion. The publication is entitled: "A Three-Part, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Mode of Action of BC 007, Neutraliser of Pathogenic Autoantibodies Against G-Protein Coupled Receptors in Healthy, Young and Elderly Subjects".

BC 007 plasma and urine concentrations were estimated by Accelero Bioanalytic GmbH on the basis of a validated enzyme-linked sandwich hybridisation assay.

The results have been published by Becker NP et al in Clinical Drug Investigation May 2020, 40(5), pages 433-447, doi: 10.1007/s40261-020-00903-9. PubMed ID: 32222912.